BioNTech SE

BioNTech SE

BNTX

拜恩泰科公司

on Thursday agreed to acquire

周四同意收购

CureVac N.V.

CureVac股份公司

CVAC

真空变压吸附（CVAC）

in an

在

all-stock transaction

全股票交易

.

。

According to the agreement, shareholders can exchange CureVac shares for around $5.46 in BioNTech ADSs. This equates, roughly, to an equity value of

根据协议，股东可以将CureVac股份换成大约5.46美元的BioNTech ADS。这大致相当于股权价值

$1.25 billion

12.5亿美元

.

。

The consideration is subject to a collar mechanism. If the 10-day volume weighted average price of the BioNTech ADSs ending on the fifth business day before the offer’s closing exceeds $126.55, the exchange ratio would be 0.04318. If the VWAP is lower than $84.37, the exchange ratio would be 0.06476..

该考量受制于一个区间机制。如果在要约结束前的第五个交易日为止的10天成交量加权平均价格（VWAP）的BioNTech美国存托股份（ADS）超过126.55美元，兑换比率将为0.04318。如果VWAP低于84.37美元，兑换比率将为0.06476。

At closing, CureVac shareholders expect to own between 4% and 6% of BioNTech.

在交易结束时，CureVac 的股东预计将拥有 BioNTech 4% 至 6% 的股份。

Also Read:

另请阅读：

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To ‘Restore Public Trust’ — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading

罗伯特·肯尼迪 Jr 解散整个 CDC 疫苗小组以“恢复公众信任”——辉瑞、莫德纳及其他生物技术股在盘后交易中下跌

With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy.

通过此次收购，BioNTech旨在加强基于mRNA的癌症免疫疗法的研究、开发、生产和商业化。

The strategic transaction will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and manufacturing.

该战略合作将完善BioNTech在mRNA设计、递送配方和制造方面的能力和专有技术。

For BioNTech, this transaction marks the next milestone in the execution of its oncology strategy which focuses on two pan-tumor programs, mRNA-based cancer immunotherapy candidates, and BNT327, a PD-L1xVEGF-A bispecific antibody candidate.

对于BioNTech来说，此次交易标志着其在执行以两种泛肿瘤项目为重点的肿瘤学战略中迈出了下一个里程碑，这两个项目分别是基于mRNA的癌症免疫治疗候选药物和BNT327（一种PD-L1xVEGF-A双特异性抗体候选药物）。

Following the transaction’s closing, CureVac’s operating subsidiary will become a wholly owned subsidiary of BioNTech. As part of this plan, BioNTech will integrate CureVac’s research and manufacturing site in Tübingen.

交易完成后，CureVac 的运营子公司将成为 BioNTech 的全资子公司。根据该计划的一部分，BioNTech 将整合 CureVac 位于图宾根的研发和制造基地。

The transaction was unanimously approved by BioNTech’s and CureVac’s management and supervisory boards. The transaction is expected to close in 2025.

该交易已获得BioNTech和CureVac的管理层和监事会一致批准。预计该交易将于2025年完成。

As of March 31, BioNTech had 15.9 billion euros in cash, cash equivalents,

截至3月31日，BioNTech拥有159亿欧元的现金及现金等价物，

and security investments

以及安全投资

.

。

Earlier in June,

早在六月，

BioNTech

BioNTech

and

和

Bristol Myers Squibb & Co

百时美施贵宝公司

.

。

BMY

百时美施贵宝公司

entered into a co-development and

进入了共同开发和

co-commercialization agreement

共同商业化协议

.

。

The pact focuses on BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.

该协议重点关注BioNTech的在研双特异性抗体BNT327在多种实体瘤类型中的应用。

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028.

百时美施贵宝将向BioNTech支付15亿美元的预付款，并在2028年之前支付20亿美元的非或有周年款项。

In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.

此外，BioNTech将有资格获得高达76亿美元的额外开发、监管和商业里程碑款项。

In March, CureVac said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify

今年 3 月，CureVac 表示欧洲专利局 (EPO) 确认了 CureVac 的欧洲专利 EP 3 708 668 B1 的有效性，但需进行修改以明确说明。

the scope of protection

保护范围

.

。

The opposition division largely dismissed BioNTech’s original opposition filed in April 2023, challenging the patent’s validity and maintaining it in amended form.

反对部门在很大程度上驳回了BioNTech于2023年4月提出的原始反对意见，质疑专利的有效性并以修正形式维持该专利。

Price Action:

价格行为:

BNTX stock is up 1.22% at $106.75, and CVAC stock is up 33.2% at $5.42 during the premarket session at the last check on Thursday.

BNTX股票在周四早盘交易中上涨1.22%，达到106.75美元，CVAC股票上涨33.2%，达到5.42美元。

Loading...

加载中...

Loading...

加载中...

Read Next:

接下来阅读：

Novavax’s Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

诺瓦瓦克斯的实验性新冠-流感联合疫苗在3期试验中显示出老年人群的免疫反应

Image: Shutterstock

图片来源：Shutterstock

CVAC

真空断路器 (CVAC)

CureVac NV

CureVac NV

$5.67

5.67美元

39.3

39.3

%

%

Stock Score Locked: Want to See it?

股票评分已锁定：想看看吗？

Benzinga Rankings give you vital metrics on any stock – anytime.

Benzinga排名为您提供任何股票的关键指标——随时。

Reveal Full Score

显示完整分数

Edge Rankings

边缘排名

Momentum

动量

80.70

80.70

Growth

增长

Not Available

不可用

Quality

质量

Not Available

不可用

Value

值

91.65

91.65

Price Trend

价格趋势

Short

短裤

Medium

中等

Long

长

Overview

概述

NVAX

诺瓦瓦克斯医药

Novavax Inc

诺瓦瓦克斯医药公司

$7.22

7.22美元

1.83

1.83

%

%

BMY

百时美施贵宝公司

Bristol-Myers Squibb Co

百时美施贵宝公司

$50.53

50.53美元

0.75

0.75

%

%

BNTX

拜恩泰科公司

BioNTech SE

BioNTech SE

$106.37

106.37美元

0.86

0.86

%

%

Market News and Data brought to you by Benzinga APIs

Benzinga API为您带来的市场新闻和数据

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

© 2025 Benzinga.com. Benzinga 不提供投资建议。保留所有权利。